Matt Martin, PharmD, BCSCP, PCCA Director of Clinical Services, reviews USP 797 revisions and impacts on compounding pharmacies in the third of a four-part series.

Our four-part series continues with Part 2, USP 795 revisions and impacts on compounding pharmacies.

Matt Martin, PharmD, BCSCP, PCCA Director of Clinical Services, reviews USP 795 & 800 revisions and impacts on compounding pharmacies in the first of a four-part series.

A.J. Day outlines how the FDA PCAC process works as well as a major development that happened with methylcobalamin at the 2021 PCAC meeting. He then explains how compounding pharmacies can help to further the process now.

Amy Shank provides an overview of H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021, a bill that would help both patients and pharmacies if passed into law. "If enacted," Amy says, "this proposal will ensure critical patient access to urgently needed medications as well as ensure that pharmacies can continue to assist with drug shortages."

Mike De Lisio explains why modular cleanrooms work well for so many pharmacies and then details the best options available for building materials, from flooring to walls to ceilings and more — all with an eye on helping pharmacies stay compliant with guidelines and regulations.

Amy Shank discusses several options available to pharmacies when attempting to cultivate closer relationships with lawmakers.

Amy Shank, PCCA's Director of Government Relations provides an exciting update about PCCA's 2021 ACT Legislative Conference, detailing the conversation between pharmacists and their legislators.

Matt Martin writes to help compounding pharmacies navigate the Food and Drug Administration’s (FDA’s) recently finalized guidance document Insanitary Conditions at Compounding Facilities.

PCCA provides clarity and guidance regarding the Food and Drug Administration (FDA) sharing its version of what a memorandum of understanding (MOU) between it and the various states would look like.